ReviewFrontiers in nutrition2026
The roles of folate, MTHFR genetics, vitamin B12 in pregnancy outcomes.
Review in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Association ofBiomedicines · 2026Article
- Reassessing Mandatory Folic Acid Fortification for Neural Tube Defect Prevention: Evidence, Uncertainty, and Policy Implications.Nutrients · 2026Review
- High-dose folic acid therapy ameliorates gut microbiota dysbiosis in reproductive-aged women with hyperhomocysteinemia.Frontiers in nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Folate is essential for fetal development, and periconceptional folic acid (FA) supplementation is well-established for preventing neural tube defects. However, evidence regarding its role in other pregnancy outcomes, such as gestational diabetes mellitus, hypertensive disorders of pregnancy, fetal growth, miscarriage, and preterm birth, remains inconsistent. Current knowledge indicates that the effects of FA are not uniform but significantly influenced by the timing, dose, and duration of supplementation, frequently exhibiting U-shaped or timing-dependent relationships. Furthermore, methylenetetrahydrofolate reductase (MTHFR) genetic polymorphisms and vitamin B12 levels are critical modifiers of folate metabolism and its association with pregnancy outcomes. Crucially, there is a lack of quantitative studies linking circulating folate levels to the risk of adverse outcomes, and no optimal threshold range has been established to balance the prevention of different complications. This review consolidates the existing evidence on the associations between FA supplementation, circulating folate levels, and non-structural pregnancy outcomes, while elucidating the modulating roles of MTHFR genetics and vitamin B12. Besides, it highlights possible underlying biological mechanism of hyperhomocysteinemia, alterations in DNA methylation, the presence of folate receptor antibody (FRAbs), and the direct anti-inflammatory effects of folate. This review aims to provide a foundation for a future precision nutrition strategy through individual physiological folate levels, MTHFR genetics, and vitamin B12 status.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.